A Phase 1, First-in-human Study of VX-433

Recruiting

Phase 1

VX-433 with MidazolamA Phase 1, First-in-human Study of VX-433

Sponsor:

Vertex Pharmaceuticals Incorporated

Code:

NCT07584434

Conditions

Narcolepsy Type 1 (NT1)

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Interventions

VX-433

Placebo

Midazolam

Bupropion

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-29. This information was provided to ClinicalTrials.gov by Vertex Pharmaceuticals Incorporated on 2026-06-08.